Multi-Omics Integration Identifies the Cholesterol Metabolic Enzyme DHCR24 as a Key Driver in Breast Cancer

Area of Science:

• Molecular Biology
• Oncology
• Metabolic Pathways

Background:

• Cholesterol metabolism is frequently altered in breast cancer (BC), but the specific molecular drivers linking metabolism to cancer progression are not fully understood.
• Identifying key mediators is crucial for understanding BC pathogenesis and developing targeted therapies.

Purpose of the Study:

• To identify molecular mediators of cholesterol metabolism in breast cancer.
• To investigate the role of identified mediators in BC progression and patient prognosis.
• To elucidate the mechanism by which DHCR24 influences the tumor microenvironment and cancer cell behavior.

Main Methods:

• Integrated multi-omics approach: Mendelian randomization, transcriptomic/proteomic database screening.
• Functional assays: DHCR24 knockdown in MCF7 cells.
• Clinical correlation: Analysis of DHCR24 mRNA expression with patient prognosis and BC subtypes (luminal, HER2+).

Main Results:

• DHCR24 was identified as a central metabolic-immune mediator in breast cancer.
• High DHCR24 mRNA expression correlates with poorer patient prognosis and is elevated in luminal and HER2+ BC subtypes.
• DHCR24 promotes BC progression non-cell-autonomously by remodeling the immunosuppressive tumor microenvironment, a role distinct from direct effects on cancer cell proliferation.

Conclusions:

• DHCR24 is a pivotal metabolic-immune node in luminal and HER2+ breast cancer.
• DHCR24's pro-tumorigenic effects are mediated through the tumor microenvironment, not intrinsic cancer cell effects.
• DHCR24 represents a promising therapeutic target for disrupting the cholesterol-immune axis in specific breast cancer subtypes.